Advertisment

Managing Fatigue in Inflammatory Rheumatic and Musculoskeletal Diseases: New Recommendations from EULAR

author-image
Mason Walker
New Update
Managing Fatigue in Inflammatory Rheumatic and Musculoskeletal Diseases: New Recommendations from EULAR

Managing Fatigue in Inflammatory Rheumatic and Musculoskeletal Diseases: New Recommendations from EULAR

Advertisment

Fatigue is a prevalent issue among individuals suffering from inflammatory rheumatic and musculoskeletal diseases (RMD). The causes of fatigue are multifaceted and not yet fully understood, but its impact on quality of life is undeniable. The European Alliance of Associations for Rheumatology (EULAR) has drafted new recommendations for fatigue management in people with an Inflammatory RMD, aiming to alleviate the severity and impact of fatigue, and help individuals develop effective coping strategies.

Advertisment

EULAR's New Recommendations

The new recommendations, presented at the 2023 EULAR congress and published in the Annals of Rheumatic Diseases, focus on the dynamic interaction of biological, psychological, and social factors. They stress the importance of monitoring fatigue, fostering shared decision-making, and implementing individualized management approaches based on patient needs and preferences.

The recommendations comprise four overarching principles and four specific recommendations. These guidelines emphasize the necessity of fatigue assessment and the benefits of two key types of interventions: physical activity and psychoeducation. While there is limited evidence for other interventions, these two approaches have shown significant promise in managing fatigue.

Advertisment

The Role of Pharmacological Interventions

Alongside the emphasis on physical activity and psychoeducation, pharmacological interventions play a key role in managing fatigue in people with Inflammatory RMDs. A systematic review published on PubMed revealed the efficacy of several drugs, such as adalimumab, golimumab, baricitinib, sarilumab, tocilizumab, tofacitinib, and secukinumab. These medications demonstrated superiority over placebo in reducing fatigue in conditions like rheumatoid arthritis and spondyloarthritis. The review also pointed out a dose/effect relationship for some of these drugs, indicating that the benefits may increase with higher doses.

RMD Open: A Valuable Resource

RMD Open, an open-access, peer-reviewed rheumatology journal, provides a wealth of information on rheumatic and musculoskeletal disorders and connective tissue diseases. It offers a variety of article types, including original research, analysis, and practice articles, along with commentaries. The editorial team offers information on editorial policies and open access, making it an excellent resource for healthcare professionals, researchers, and patients alike. The journal's latest articles cover topics such as the spine, systemic sclerosis, autoimmunity, inflammatory arthritis, and treatments.

Finally, managing fatigue in individuals with Inflammatory RMDs requires a comprehensive strategy that includes biological, psychological, and social aspects. The new EULAR recommendations, along with pharmacological interventions and resources like RMD Open, offer valuable tools for healthcare teams to better support their patients in identifying and addressing fatigue. By implementing these strategies, we can help improve the quality of life for those living with Inflammatory RMDs.

Musculoskeletal Disorders Physical Activity Fatigue Inflammatory Rheumatic Adalimumab
Advertisment
Chat with Dr. Medriva !